IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

Published:2016-11 Issue:11 Volume:17 Page:1599-1611
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rini Brian I,Stenzl Arnulf,Zdrojowy Romauld,Kogan Mikhail,Shkolnik Mikhail,Oudard Stephane,Weikert Steffen,Bracarda Sergio,Crabb Simon J,Bedke Jens,Ludwig Joerg,Maurer Dominik,Mendrzyk Regina,Wagner Claudia,Mahr Andrea,Fritsche Jens,Weinschenk Toni,Walter Steffen,Kirner Alexandra,Singh-Jasuja Harpreet,Reinhardt Carsten,Eisen Tim

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy;Fyfe;J Clin Oncol,1995

2. Pazopanib versus sunitinib in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2013

3. Integrated functional genomics approach for the design of patient-individual antitumor vaccines;Weinschenk;Cancer Res,2002

4. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy;Singh-Jasuja;Cancer Immunol Immunother,2004

5. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund’s adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants;Schaed;Clin Cancer Res,2002

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Insight into Immunological Therapeutic Approach against Cancer: Potential Anti-Cancer Vaccines;Current Genomics;2024-08-30

2. Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective;Vaccines;2024-08-22

3. A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma;Esophagus;2024-07-11

4. Orchestrated Codelivery of Peptide Antigen and Adjuvant to Antigen-Presenting Cells by Using an Engineered Chimeric Peptide Enhances Antitumor T-Cell Immunity;Cancer Immunology Research;2024-04-17

5. Are we getting closer to a successful neoantigen cancer vaccine?;Molecular Aspects of Medicine;2024-04